Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bcl-XL_42-CAF09b Vaccine in Prostate Cancer
NCT03412786Phase 1Completed
- Sponsor
- Herlev Hospital
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of Bcl-Xl_42 + CAF09b in prostate cancer (PCa) (2 arms), sponsored by Herlev Hospital. Primary endpoint: Number and type of reported adverse events. Started May 2018; status: completed.
02
Drugs
Bcl-Xl_42 + CAF09b
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03412786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412786.